Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells

@article{Zhang2009LentivirusesWT,
  title={Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells},
  author={K-x Zhang and Maryam Moussavi and Chul-Ho Kim and Elaine K. Chow and Irvin S. Y. Chen and Ladan Fazli and William WeiGuo Jia and Paul S. Rennie},
  journal={Cancer Gene Therapy},
  year={2009},
  volume={16},
  pages={820-831}
}
In this study, we took advantage of the overexpression of human epidermal growth factor receptor 2 (HER-2) in prostate cancers to design lentiviruses with modified envelope proteins that bind antibodies to specific cell-surface antigens. When bound to trastuzumab (Herceptin, Genentech, CA), lentiviruses were able to selectively infect androgen-sensitive LNCaP and castration-resistant C4-2 human prostate cancer cell lines, both of which express high levels of HER-2. To test for a therapeutic… CONTINUE READING